

**AHNCI COLON AND RECTAL TUMOR BOARD**

Friday, July 12, 2019

7:00-8:00 am

Pugh Classroom, 2nd floor, AHNCI

Please join from your computer, tablet or smartphone at:

Zoom: <https://zoom.us/j/607840068>

Phone:  646-558-8656  Meeting ID: 607 840 068

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case** | **De-identified patient** | **Reason** | **Presenter** |
| 1 | LC/  MRN 11012140 | Path review colon cancer | RF |
| 2 | CR/ MRN: 11604402 | 53 y/o male with clinical stage T1N0 rectal cancer s/p full-thickness transanal excision via TEMS on 6/28/19. Request NAPRC pathology review. | RF |
| 3 | VP/ MRN: 11344337 | Record review | RF |
| 4 | DM//MRN: 11607054 | 50 yo M with newly diagnosed sigmoid colon cancer and malignant colocutaneous fistula. | AR |
| 5 | KS/MRN: 43146 | 83 yo male with rectal bleeding who had a colonoscopy done on 6/27/19 which showed a sigmoid polyp that was removed and was invasive moderately differentiated adenocarcinoma and a mass at 13 cm from the anal verge that was biopsied and came back as invasive moderately differentiated adenocarcinoma.  MRI Pelvis and CT Chest being completed 7/5/19. | JM |
| 6 | MM/MRN: 26096 | 74 y/o female with rectosigmoid mass consistent with tubulovillous adenoma with high grade dysplasia on biopsy s/p robotic LAR with diverting loop ileostomy on 6/12/19. **Requesting pathology review**. | MV |
| 7 | MS/MRN: 10285854 | 61 y/o female with clinical stage T2N0 rectal cancer s/p laparoscopic robotic ultra-low anterior resection with DLI on 6/26/19. **NAPRC pathology review** | MV |
| 8 | BB/ MRN: 280819 | 70 y/o female with clinical stage T3N1 rectal cancer s/p standard neoadjuvant chemoradiotherapy and laparoscopic low anterior resection with DLI on 7/3/19. **NAPRC pathology review.** | MV |
| 9 | MS/MRN: 962987 | 48 y/o female with Stage IV metastatic sigmoid colon cancer to the liver and lungs who had colonic stent placed in March 2019 and completed 6 cycles of Folfiri. She recently  underwent laparoscopic robotic sigmoid colectomy on 6/20/19 for concern of obstructive symptoms and plan per oncology to begin avastin. | MV |
| 10 | MB/MRN: 6045 | 89 y/o female with newly diagnosed rectal cancer. | SN |
| 11 | DM/MRN: 10727518 | 47 year old male with rectal cancer 11/18.  Has received FOLFOX, concurrent chemo/rad and was then placed on the FR2 trial and had 2 doses of Darvalumab. Developed back pain over the past several weeks.  CT on 7/8 shows numerous pulmonary mets and spinal mets. | NA |
| 12 | RK/MRN: 136096 | 47 y/o male with metastatic rectal cancer to the liver previously discussed at cancer conference with recommendations for biopsy of enlarged right external iliac lymph node. **Request pathology review from biopsy results** | MV |
| 13 | AV/MRN: 887120 | 86 y/o female with 12mm multi-lobulated transverse colon polyp s/p hot snare polypectomy on 2/6/19. Pathology was consistent with invasive moderately adenocarcinoma with carcinoma present at cauterized edge. Patient declining any surgical intervention | MV |
| 14 | CM/MRN: 11657645 | 54 y/o female with newly diagnosed rectosigmoid adenocarcinoma | SN |

AHN CME Credit

**TEXT 412-** **412-301-9919**save this number to your contacts–  
will use this **same** number every week to text your attendance

**Today’s SMS Code:** FUYREW

You must text within THREE hours of the tumor board. You will receive a text confirming receipt and then an email to complete the evaluation. Once the evaluation is completed credit is registered.

Objectives

Upon completion of this activity, participants will have a better understanding of decision-making for complex colon and rectal problems and be armed with clinical pathways to improve care.

Accreditation:

Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians. Allegheny General Hospital designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).  The speakers have nothing to disclose.

Moderators: Alexander Kirichenko, MD /Dulabh Monga, MD /James McCormick, DO/Richard Fortunato, MD